Hemostemix Inc.

Hemostemix Inc.

HMTXF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$5.47M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Hemostemix Inc.Hemostemix Inc.-2-78%--0.6
$-0.01

Current Fair Value

146.8% downside

Overvalued by 146.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$5.47 Million
Enterprise Value$8.90 Million
Earnings per Share$-0.03
Beta0.61
Outstanding Shares204,994,910

Return

Return on Equity78.43%ROE
Return on Assets-1758.21%
Return on Invested Capital251.88%

Valuation & Multiples

P/E Ratio-2.02P/E Ratio
PEG-2.04PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.03Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-2.06
Enterprise Value to Net Income-2
Total Debt to Enterprise0.4
Debt to Equity-0.62Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 31, 2026
EPS
-$0.00
Reported
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
November 27, 2026
EPS Estimate
-
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Hemostemix Inc.

12 employees
CEO: Thomas A. Smeenk

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for t...